Practical recommendations for the use of the alpha-glutamyl-tryptophan for respiratory diseases

• Anna A. Ruleva
• Vera A. Apryatina
• Yulia E. Konstantinova
• Ksenia K. Tihomirova

Abstract

Respiratory diseases vary widely from acute infections to chronic conditions. Acute diseases of the respiratory tract occupy the overwhelming majority of cases among infectious pathology and each year take on the character of epidemics. In turn, chronic bronchopulmonary diseases, primarily chronic obstructive pulmonary disease (COPD) and bronchial asthma are socially significant and always remain in the center of attention of specialists. Today 65 million of people suffer from COPD in moderate or severe form [1], bronchial asthma - 235 million of people. It is the most common chronic disease among children [2]. In this case, the layering of respiratory infections on chronic pathology is the main factor leading to an exacerbation of the latter and the progression of the course of the disease.

One of the important causes of morbidity, protracted and complicated course of exacerbations of COPD, biofeedback and pneumonia is the altered immune reactivity of the population of various origins, associated, among other things, with unfavorable environmental factors of the modern world. In this regard, it is advisable to use immunomodulators in terms of correcting changes in immunological parameters against the background of the underlying disease, as well as for the prevention of intercurrent infections stratification and the treatment of exacerbations.

The review presents the results of previous clinical studies on the use of the Timogen^® (alpha-glutamyl-tryptophan) for the treatment of bronchopulmonary diseases, both in adult and in children. Practical recommendations are given for the use of alpha-glutamyl-tryptophan in various nosological forms and depending on age.

Keywords:respiratory diseases; Timogen®; practical recommendations; children; adults

References

1. VOZ. Burden of chronic obstructive disease [Electronic resource]. URL: https://www.who.int/respiratory/copd/burden/ru/ (in Russian)

2. VOZ. Аsthma. basic facts [Electronic resource]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/asthma (in Russian)

3. Logashenko E.B. Molecular and cellular mechanisms (COPD). Abstracts for the report at the conference. All-Russian multi-conference with international participation «Biotechnology – in the medicine of the future» 29.06.2019. Novosibirks [Electronic resource]. URL: https://elibrary.ru/download/elibrary_39106934_3689283 1.pdf (in Russian)

4. Taylor A.E., Finney-Hayward T.K., Quint J.K., et al. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 2010; 35: 1039–47.

5. Korovkina E.S., Kostinov M.P., Kazharova S.V. The possibilities of using immunomodulators in the complex therapy of community-acquired pneumonia. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2017; 4: 101–11. (in Russian)

6. Mavzyutova G.A., Mukhamadieva L.R., Fazlyeva R.M. Clinical approach to immunocorrection in community-acquired pneumonia. Meditsinskiy sovet. Bronkhopul’monologiya. 2017; 11: 58–63. (in Russian)

7. Zaplatnikov A.L., Girina A.A. To the problem of «frequently ill children». Pediatriya. Zhurnal imeni G.N. Speranskogo. 2015; 4: 215–20. (in Russian)

8. Samsygina G.A. The problem of frequently ill children in pediatrics. Pediatriya. Zhurnal imeni G.N. Speranskogo. 2015; 4: 211–4. (in Russian)

9. Kurtasova L.M., Shakina N.A. Features of the immune response and metabolic changes in peripheral blood lymphocytes in young children with recurrent obstructive bronchitis. Meditsinskaya immunologiya. 2017; 19 (5): 597–604. (in Russian)

10. National program «Bronchial asthma in children. Treatment and prevention strategy». 5th ed. 2017. (in Russian)

11. Simovan’yan E.N., Denisenko V.B. Improving the treatment of acute obstructive bronchitis associated with ARVI in young children. Pediatriya. Zhurnal imeni G.N. Speranskogo. 2018; 97 (1): 65–70. (in Russian)

12. Petlenko S.V., Golovacheva E.G., Afanas’eva O.I. Possibilities of immunocorrection to reduce the incidence of people in areas with unfavorable occupational and environmental factors. Meditsinskaya immunologiya. 2020; 22 (6): 1097–110. (in Russian)

13. Sokolova T.M., Poloskov V.V., Shuvalov A.N., Burova O.S., Sokolova Z.A. Signaling TLR / TLR-mechanisms of immunomodulatory action of the drugs Thymogen and Ingavirin. Rossiyskiy bioterapevticheskiy zhurnal. 2019; 18 (1): 60–6. (in Russian)

14. Ershov A.F., Ogorodnikova L.M. Prevention of allergic reactions in patients with pneumonia. In: Abstracts of reports of the 6th National Congress on Respiratory Diseases. Novosibirsk, 1996. Ref. 1303. (in Russian)

15. Khavinson V.X., Sinakevich N.V., Seriy S.V. Timogen. Saint Petersburg, 1991: 46 p. (in Russian)

16. Litvinova N.V., Eremeev V.V., Abramova Z.P., et al. Changes in immunological and nonspecific reactivity in patients with chronic purulent-obstructive bronchitis in complex treatment with the use of thymogen. Problemy tuberkuleza. 1994; 4: 48–50. (in Russian)

17. Gerasimenko O.N., Krivosheya L.M., Myasoed Yu.P., Agafonova E.A. Combined use of thymogen and eubiotics in the treatment of recurrent bronchitis in children. In: Peptide bioregulators-cytomedines. Saint Petersburg, 1992: 43 p. (in Russian)

18. Zoloedov V.I., Zemskov A.M., Stupnitsky A.A., Goryaninova T.A. Treatment with thymogen and myelopid in patients with bronchial asthma. Klinicheskaya meditsina. 1995; 73 (6): 43–5. (in Russian)

19. Clinical pharmacology of Thymogen. In: V.S. Smirnov (ed.). Saint Petersburg: AJSING, 2012: 108 p. (in Russian)

20. Tixomirova A.R., Ruleva A.A. Clinical and immunological efficacy of a domestic immunotropic drug in children with acute respiratory infections with bronchoobstructive syndrome. Immunologiya. 2020; 41 (3): 249–55. (in Russian)

21. Lyubimov D.S., Britanov A.N. Predictors of the effectiveness of T-cell mimetics in the correction of immune and endocrine dysfunction. In: VII International Symposium «Interaction of the nervous and immune systems in health and disease». Saint Petersburg, May 27–31, 2019. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)